<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table2" position="float"><object-id pub-id-type="doi">10.7554/eLife.31579.010</object-id><label>Table 2.</label><caption><title>Adjusted Incidence Rate Ratios (aIRR) for uncomplicated malaria and non-malarial diseases in Kenya by <italic>Sl</italic> and <italic>McC</italic> genotype*.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Clinical <break/>Outcomes</th><th valign="top"><italic>Sl2&#160;</italic>aIRRs<sup>&#8224;</sup> (95% CI)</th><th valign="top"><italic>P</italic> value</th><th valign="top"><italic>McC<sup>b</sup></italic> aIRRs (95% CI)</th><th valign="top"><italic>P</italic> value</th></tr></thead><tbody><tr><td valign="top">Uncomplicated malaria</td><td valign="top"><bold>0.49 (0.34&#8211;0.72)</bold><sup>&#8225;</sup></td><td valign="top"><bold>&lt;0.001 <sup>4</sup></bold></td><td valign="top">1.24 (0.90&#8211;1.70)</td><td valign="top">0.184 <bold><sup>1</sup></bold></td></tr><tr><td valign="top">All non-malaria clinical visits</td><td valign="top">1.13 (0.96&#8211;1.32)</td><td valign="top">0.140 <bold><sup>1</sup></bold></td><td valign="top"><bold>0.76 (0.61&#8211;0.96)<sup>&#8225;</sup></bold></td><td valign="top"><bold>0.020 <sup>4</sup></bold></td></tr><tr><td valign="top">LRTI<sup>&#167;</sup></td><td valign="top">1.09 (0.81&#8211;1.47)</td><td valign="top">0.561 <bold><sup>1</sup></bold></td><td valign="top"><bold>0.39 (0.16&#8211;0.96)</bold></td><td valign="top"><bold>0.040 <sup>1</sup></bold></td></tr><tr><td valign="top">URTI<sup>#</sup></td><td valign="top">1.21 (0.98&#8211;1.50)</td><td valign="top">0.073 <bold><sup>1</sup></bold></td><td valign="top"><bold>0.79 (0.63&#8211;0.99)</bold></td><td valign="top"><bold>0.047 <sup>3</sup></bold></td></tr><tr><td valign="top">Gastroenteritis</td><td valign="top">0.66 (0.43&#8211;1.03)</td><td valign="top">0.066 <bold><sup>2</sup></bold></td><td valign="top"><bold>0.55 (0.31&#8211;0.97)<sup>&#8225;</sup></bold></td><td valign="top"><bold>0.038 <sup>2</sup></bold></td></tr><tr><td valign="top">Skin infection</td><td valign="top">1.33 (0.79&#8211;2.26)</td><td valign="top">0.285 <bold><sup>2</sup></bold></td><td valign="top">0.42 (0.16&#8211;1.13)</td><td valign="top">0.086 <bold><sup>1</sup></bold></td></tr><tr><td valign="top">Helminth infection</td><td valign="top">1.98 (0.83&#8211;4.71)</td><td valign="top">0.122 <bold><sup>2</sup></bold></td><td valign="top">0.68 (0.43&#8211;1.07)</td><td valign="top">0.094 <bold><sup>4</sup></bold></td></tr><tr><td valign="top">Malaria negative fever</td><td valign="top">0.83 (0.58&#8211;1.18)</td><td valign="top">0.293 <bold><sup>2</sup></bold></td><td valign="top">1.03 (0.80&#8211;1.33)</td><td valign="top">0.828 <bold><sup>3</sup></bold></td></tr></tbody></table><table-wrap-foot><fn><p>*Data were collected from 22 <italic>Sl1/Sl1</italic>, 94 <italic>Sl1/Sl2</italic> and 92 <italic>Sl2/Sl2</italic> individuals during 49.4, 213.8 and 188.8 cyfu (child-years of follow-up), respectively, and 137 <italic>McC<sup>a</sup>/McC<sup>a</sup></italic>, 63 <italic>McC<sup>a</sup></italic>/<italic>McC<sup>b</sup></italic> and 8 <italic>McC<sup>b</sup>/McC<sup>b</sup></italic> individuals during 294.5, 143.2 and 14.3 cyfu, respectively. Both <italic>Sl2</italic> and <italic>McC<sup>b</sup></italic> alleles were tested for their association with the disease outcomes of interest using Poisson regression in the <bold><sup>1</sup></bold>recessive, <bold><sup>2</sup></bold>dominant, <bold><sup>3</sup></bold>heterozygous and <bold><sup>4</sup></bold>additive models. The best fitting models as examined using the Akaike information criterion (AIC) were used in the final analysis that included adjustment for <italic>McC</italic> genotype (for <italic>Sl</italic> analyses), <italic>Sl</italic> genotype (for <italic>McC</italic> analyses) &#945;<sup>+</sup>thalassaemia and sickle cell genotype, ABO blood group, season (divided into 3 monthly blocks), ethnicity, age as a continuous variable and within-person clustering of events.</p><p><sup>&#8224;</sup>aIRRs: adjusted Incidence Rate Ratios.</p></fn><fn><p><sup>&#8225;</sup>Models that showed significant evidence of interaction between either <italic>Sl2</italic> or <italic>McC<sup>b</sup></italic> and &#945;<sup>+</sup>thalassaemia.</p><p><sup>&#167;</sup>LRTI: Lower Respiratory Tract Infection.</p></fn><fn><p><sup>#</sup>URTI: Upper Respiratory Tract Infection.</p></fn></table-wrap-foot></table-wrap>